One of the joys of oncology research is that it’s data driven, which means companies can quite clearly see how others have fared, and where the gaps and opportunities lie for new product development.

There is always the potential to unlock the gates to the “secret garden,” whether it be targeting a tumour type previously considered intractable, treating an unmet medical need where there are few or no effective therapies, or in the case of immuno-oncology, manipulating the tumour microenvironment in a way that leads to an improvement in the long tail of survival we’re all looking for.

In addition to improved outcomes, you also need a safety profile with a favourable benefit/risk ratio, where there aren’t intolerable or life changing side effects or an increased risk of death. Who said it was easy?

Innovation takes many forms, and in this post we’re looking at how one biotech company may have unlocked the key to a secret garden through the optimised design of their molecule.  As always, it’s early days although it’s good to see companies looking to solve hard problems because the easy low hanging fruit wins in immuno-oncology went a long time ago.

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by